Your browser doesn't support javascript.
loading
Parallel evolution and differences in seroprevalence of SARS-CoV-2 antibody between patients with cancer and health care workers in a tertiary cancer centre during the first and second wave of COVID-19 pandemic: canSEROcov-II cross-sectional study.
Ladoire, Sylvain; Rederstorff, Emilie; Goussot, Vincent; Parnalland, Sophie; Briot, Nathalie; Ballot, Elise; Truntzer, Caroline; Ayati, Siavoshe; Bengrine-Lefevre, Leila; Bremaud, Nathalie; Coudert, Bruno; Desmoulins, Isabelle; Favier, Laure; Fraisse, Cléa; Fumet, Jean-David; Hennequin, Audrey; Hervieu, Alice; Ilie, Silvia; Kaderbhai, Courèche; Lagrange, Aurélie; Martin, Nils; Mazilu, Irina; Mayeur, Didier; Palmier, Rémi; Simonet-Lamm, Anne-Laure; Vincent, Julie; Zanetta, Sylvie; Arnould, Laurent; Coutant, Charles; Bertaut, Aurélie; Ghiringhelli, François.
Afiliação
  • Ladoire S; Department of Medical Oncology, Centre Georges François Leclerc, Dijon, France; Research Platform in Biological Oncology, Georges François Leclerc Cancer Center, Dijon, France; Centre de Recherche INSERM LNC-UMR1231, Dijon, France; University of Burgundy-Franche Comté, France. Electronic address: sl
  • Rederstorff E; Clinical Research Center (CRC), Centre Georges François Leclerc, Dijon, France.
  • Goussot V; Department of Pathology and Tumor Biology, Centre Georges François Leclerc, Dijon, France.
  • Parnalland S; Clinical Research Center (CRC), Centre Georges François Leclerc, Dijon, France.
  • Briot N; Methodology and Biostatistics Unit, Centre Georges François Leclerc, Dijon, France.
  • Ballot E; Research Platform in Biological Oncology, Georges François Leclerc Cancer Center, Dijon, France; Centre de Recherche INSERM LNC-UMR1231, Dijon, France; Bioinformatic Core Facility Georges-François Leclerc Cancer Center, Dijon, France.
  • Truntzer C; Research Platform in Biological Oncology, Georges François Leclerc Cancer Center, Dijon, France; Centre de Recherche INSERM LNC-UMR1231, Dijon, France; Bioinformatic Core Facility Georges-François Leclerc Cancer Center, Dijon, France.
  • Ayati S; Department of Medical Oncology, Centre Georges François Leclerc, Dijon, France.
  • Bengrine-Lefevre L; Department of Medical Oncology, Centre Georges François Leclerc, Dijon, France.
  • Bremaud N; Department of Medical Oncology, Centre Georges François Leclerc, Dijon, France.
  • Coudert B; Department of Medical Oncology, Centre Georges François Leclerc, Dijon, France.
  • Desmoulins I; Department of Medical Oncology, Centre Georges François Leclerc, Dijon, France.
  • Favier L; Department of Medical Oncology, Centre Georges François Leclerc, Dijon, France.
  • Fraisse C; Department of Medical Oncology, Centre Georges François Leclerc, Dijon, France.
  • Fumet JD; Department of Medical Oncology, Centre Georges François Leclerc, Dijon, France.
  • Hennequin A; Department of Medical Oncology, Centre Georges François Leclerc, Dijon, France.
  • Hervieu A; Department of Medical Oncology, Centre Georges François Leclerc, Dijon, France.
  • Ilie S; Department of Medical Oncology, Centre Georges François Leclerc, Dijon, France.
  • Kaderbhai C; Department of Medical Oncology, Centre Georges François Leclerc, Dijon, France.
  • Lagrange A; Department of Medical Oncology, Centre Georges François Leclerc, Dijon, France.
  • Martin N; Department of Medical Oncology, Centre Georges François Leclerc, Dijon, France.
  • Mazilu I; Department of Medical Oncology, Centre Georges François Leclerc, Dijon, France.
  • Mayeur D; Department of Medical Oncology, Centre Georges François Leclerc, Dijon, France.
  • Palmier R; Department of Medical Oncology, Centre Georges François Leclerc, Dijon, France.
  • Simonet-Lamm AL; Department of Medical Oncology, Centre Georges François Leclerc, Dijon, France.
  • Vincent J; Department of Medical Oncology, Centre Georges François Leclerc, Dijon, France.
  • Zanetta S; Department of Medical Oncology, Centre Georges François Leclerc, Dijon, France.
  • Arnould L; Research Platform in Biological Oncology, Georges François Leclerc Cancer Center, Dijon, France; Department of Pathology and Tumor Biology, Centre Georges François Leclerc, Dijon, France.
  • Coutant C; University of Burgundy-Franche Comté, France; Department of Oncologic Surgery, Centre Georges François Leclerc, Dijon, France.
  • Bertaut A; Methodology and Biostatistics Unit, Centre Georges François Leclerc, Dijon, France.
  • Ghiringhelli F; Department of Medical Oncology, Centre Georges François Leclerc, Dijon, France; Research Platform in Biological Oncology, Georges François Leclerc Cancer Center, Dijon, France; Centre de Recherche INSERM LNC-UMR1231, Dijon, France; University of Burgundy-Franche Comté, France.
Eur J Cancer ; 165: 13-24, 2022 04.
Article em En | MEDLINE | ID: mdl-35189537
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: COVID-19 / Neoplasias Tipo de estudo: Guideline / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Eur J Cancer Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: COVID-19 / Neoplasias Tipo de estudo: Guideline / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Eur J Cancer Ano de publicação: 2022 Tipo de documento: Article